Top

Published in:

01-09-2012 | Research Article

Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients

Authors: Lijun Di, Yulin Zhu, Jun Jia, Jing Yu, Gonghong Song, Jie Zhang, Li Che, Huabing Yang, Yan Han, Bo Ma, Chunrong Zhang, Yanhua Yuan, Miaoning You, Fengling Wan, Xiaoli Wang, Xinna Zhou, Jun Ren

Published in: Clinical and Translational Oncology | Issue 9/2012

Abstract

Aim

The aim of the study is to explore the safety of cytotoxic T lymphocytes (CTLs) infusion by transfected dendritic cells (DCs) with recombinant adeno-associated virus vector (rAAV) carrying CEA cDNA among advanced cancer patients.

Patients and Methods

A total of 27 cancer patients with tumor tissue expression positivity and/or sera-elevated level of CEA were subsequently divided into cohort A and B resulted from the ex vivo expansion number of CTLs generated from co-culture of specific transfected DCs with autologous T lymphocytes. Based on the variations of infused number of specific CTL derived from different yields of individualized patients who had experienced various anti-cancer treatments, we compared the patients of low number of CTL cells (2–8 × 10⁸ infused, cohort A, 6 cases) with those of higher number (above 8 × 10⁸ infused, cohort B, 21 cases) to testify the possible adverse reactions caused by amount of infused CTLs. This study resembled a phase I study aiming for setting up clinical trial of adoptive cellular therapy that conceptually comes from conventional cytotoxic drugs.

Results

The results showed that one case from the each cohort had experienced moderate fever, and four cases with fatigue were seen in cohort B. The symptoms were transient without serious adverse events. For the consideration of clinical response 2 partial remission (8.0 %, 2/25), 1 minor remission, and 9 stable disease (40 %, 10/25) were observed in 25 patients eligible for evaluation. Sera levels of CEA assay were lowered in six patients. During a median follow-up of 8.1 months, we could not observe severe or chronic adverse reactions related to rAAV-DC infusions. Meanwhile, the variation of number of CTLs infused in this setting did not alter the status of peripheral lymphocyte population.

Conclusions

These preliminary data suggest that the rAAV-DC immunotherapy is well-tolerated and showed no severe adverse reactions in cancer patients.

Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27:83–117PubMedCrossRef

Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308PubMedCrossRef

Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F (1991) Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int J Cancer 49(1):19–24PubMedCrossRef

Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232):807–820CrossRef

Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29(3):372–383PubMedCrossRef

Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ (2008) Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57(10):1559–1568PubMedCrossRef

Decker WK, Xing D, Shpall EJ (2006) Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transpl 12(2):113–125CrossRef

Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A (2007) Current approaches in dendritic cell generation implications for cancer immunotherapy. Cancer Immunol Immunother 56(10):1513–1537PubMedCrossRef

Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195(10):1279–1288PubMedCrossRef

10.

Höltl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr, Thurnher M (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8(11):3369–3376PubMed

11.

Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG (2001) Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167(12):7150–7156PubMed

12.

Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, Strong R, Leggett B, Powell L, Maddern G, Ellem K, Cooksley G (2002) Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 17(8):889–896PubMedCrossRef

13.

Maier T, Tun-Kyi A, Tassis A, Jungius KP, Burg G, Dummer R, Nestle FO (2003) Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102(7):2338–2344PubMedCrossRef

14.

Zhang L, Zhang H, Liu W, Wang H, Jia J, Si X, Ren J (2005) Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA. Cell Immunol 238(1):61–66PubMedCrossRef

15.

Zhang HM, Zhang LW, Ren J, Fan L, Si XM, Liu WC (2006) Induction of alpha-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells. Cell Immunol 239(2):144–150PubMedCrossRef

16.

Zhang HM, Zhang LW, Liu WC, Cheng J, Si XM, Ren J (2006) Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy 8(6):580–588PubMedCrossRef

17.

Yang JY, Cao DY, Liu WC, Zhang HM, Teng ZH, Ren J (2006) Dendritic cell generated from CD34+ hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses. Cell Immunol 240(1):14–21PubMedCrossRef

18.

Ren J, Jia J, Zhang H, Zhang L, Ma B, Jiang H, Di L, Song G, Yu J (2008) Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma. Cancer Sci 99(7):1420–1426PubMedCrossRef

19.

Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21(4):583–593PubMedCrossRef

20.

Robert-Guroff M (2007) Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 18(6):546–556PubMedCrossRef

21.

Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369(9579):2097–2105PubMedCrossRef

22.

Mahadevan M, Liu Y, You C, Luo R, You H, Mehta JL, Hermonat PL (2007) Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol Immunother 56(10):1615–1624PubMedCrossRef

23.

Chiriva-Internati M, Liu Y, Weidanz JA, Grizzi F, You H, Zhou W, Bumm K, Barlogie B, Mehta JL, Hermonat PL (2003) Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 102(9):3100–3107PubMedCrossRef

24.

Dudley ME, Rosenberg SA (2007) Adoptive cell transfer therapy. Semin Oncol 34(6):524–531PubMedCrossRef

25.

June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117(6):1466–1476PubMedCrossRef

26.

Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673):245–252PubMedCrossRef

27.

Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10(5):475–480PubMedCrossRef

28.

Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C (2004) Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 9(5):757–764PubMedCrossRef

29.

Oh ST, Kim CH, Park MY, Won EH, Sohn HJ, Cho HI, Kang WK, Hong YK, Kim TG (2006) Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 24(15):2860–2868PubMedCrossRef

30.

Steinman RM (2007) Dendritic cells: understanding immunogenicity. Eur J Immunol 37(Suppl 1):S53–S60PubMedCrossRef

Title: Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients
Authors: Lijun Di
Yulin Zhu
Jun Jia
Jing Yu
Gonghong Song
Jie Zhang
Li Che
Huabing Yang
Yan Han
Bo Ma
Chunrong Zhang
Yanhua Yuan
Miaoning You
Fengling Wan
Xiaoli Wang
Xinna Zhou
Jun Ren
Publication date: 01-09-2012
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 9/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0854-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Patients and Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2012

The association of annexin A2 and cancers

Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

Chemotherapy at the end of life: up until when?

Trends in the lung cancer incidence and mortality in the Slovak and Czech Republics in the contexts of an international comparison

Immunohistochemical expression of cyclooxygenase-2 in patients with advanced cancer of the larynx who have undergone induction chemotherapy with the intention of preserving phonation

Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer